Illustration of DNA strands and key genes involved in lupus research, symbolizing genetic discoveries.

Decoding Lupus: How Genetic Clues Could Revolutionize Treatment

Avery Sinclair monogram
Avery Sinclair in Health & Wellness October 2026 • 5 min read.

"New research reveals how copy number variations in our genes may hold the key to understanding and treating systemic lupus erythematosus."


Systemic lupus erythematosus (SLE), often simply called lupus, is a chronic autoimmune disease that can affect almost any part of the body. Characterized by inflammation and a wide range of symptoms, from fatigue and joint pain to skin rashes and organ damage, lupus can be challenging to diagnose and manage. While the exact causes of lupus remain elusive, it's widely accepted that genetics play a significant role in its development.

Recent advancements in genetic research are beginning to unravel the intricate web of factors contributing to lupus. A fascinating area of study is copy number variation (CNV), which refers to differences in the number of copies of specific genes within an individual's DNA. Unlike single-gene mutations, CNVs involve larger segments of DNA and can have profound effects on gene expression and function. New research is revealing how these CNVs may influence a person's susceptibility to lupus and potentially pave the way for more targeted therapies.

This article delves into the latest findings on CNVs and their connection to lupus. We will explore the groundbreaking study that examined the role of CNVs in a diverse population, the specific genes implicated, and the potential implications for future treatments. This information offers a fresh perspective on how genetics influences complex diseases like lupus and offers hope for a better future for those affected.

AI Search Multiple angles on this topic

Lupus Burden

Systemic lupus erythematosus is a chronic autoimmune disease that can cause widespread inflammation and tissue damage throughout the body. Its effects and severity vary considerably among individuals, so the overall health impact is difficult to capture with a single measure. This variability can affect organs, symptoms, disease activity, and quality of life.

Current Care

Lupus care generally relies on clinical assessment, laboratory measurements, disease-activity monitoring, and treatments tailored to the organs and symptoms involved. Because lupus can change over time and present differently between people, no single approach reliably predicts every patient's course. Existing management therefore remains individualized, with continuing limitations in early diagnosis, disease measurement, and long-term control.

From Mystery to Chronic Disease

Lupus was once regarded as a mysterious and often deadly disease. Advances in diagnosis and management have helped shift it toward a chronic condition for many patients. Even so, quality-of-life problems and comorbid complications remain important challenges.

Unveiling the Genetic Puzzle: The Role of Copy Number Variations in Lupus

Illustration of DNA strands and key genes involved in lupus research, symbolizing genetic discoveries.

The research, published in PLOS ONE, focused on a specific type of genetic variation: copy number variations (CNVs). CNVs represent differences in the number of copies of a particular gene within a person's genome. This study employed a case-control design, comparing the genomes of individuals with lupus to those without the disease. The researchers used advanced genomic tools to detect and analyze CNVs across the entire genome.

The study identified several key findings. Notably, the researchers found a synergistic effect between the FCGR3B and ADAM3A genes. When deletions (missing copies) were present in both genes, the risk of developing lupus increased significantly. This suggests that these genes may interact in a way that influences the development of the disease. Furthermore, the study identified several rare CNVs in lupus patients, and for the first time, described heterozygous deletions in the CFHR4, CFHR5, and HLA-DPB2 genes.

  • The study examined CNVs in SLE patients and healthy controls.
  • Researchers found a synergistic effect between FCGR3B and ADAM3A genes.
  • Deletions in both genes increased lupus risk.
  • Rare CNVs were identified, including deletions in CFHR4, CFHR5, and HLA-DPB2.
AI Search Multiple angles on this topic

Research Frontiers

Recent reviews describe systemic lupus erythematosus as a heterogeneous disease with complex pathogenesis, varied clinical manifestations, and an unpredictable course. A study highlighted by Nature Reviews Rheumatology reports that Epstein–Barr virus can reprogramme autoreactive B cells into pathogenic antigen-presenting cells, offering a possible mechanistic link to SLE. The 2026 One Year in Review analysis focuses on emerging pathogenetic insights and novel or refined developments reported during 2025, while Nature characterizes SLE as capable of causing widespread inflammation and tissue damage. (Reference URL 1: https://www.nature.com/subjects/systemic-lupus-erythematosus/nrrheum; Reference URL 2: https://www.clinexprheumatol.org/article.asp?a=23680)

Persistent Limitations

The major challenge is lupus heterogeneity: symptoms and disease activity can differ between people and can change within the same person over time. This complicates early diagnosis, accurate measurement of activity, and prediction of disease course, leaving substantial unmet medical need. Unpredictable flares, progressive organ risk, and treatment burden remain concerns despite advances in understanding and care. Reported complications include kidney failure, stroke, heart attack, pregnancy complications, cataracts, bone fractures, and cardiovascular disease; Johns Hopkins notes that cardiovascular disease, rather than lupus itself, is the leading cause of death in people with lupus. (Reference URL 1: https://pmc.ncbi.nlm.nih.gov/articles/PMC8193052/; Reference URL 2: https://www.hopkinsmedicine.org/health/conditions-and-diseases/lupus/lupus-complications-and-prognosis)

A Personalized Comparison

Comparing lupus strategies is difficult because the disease does not follow one consistent pattern across patients or across time. A treatment or monitoring approach may appear effective for one clinical presentation while offering less benefit for another. The most meaningful comparisons therefore need to account for organ involvement, disease activity, flares, treatment burden, and quality of life rather than relying on a single outcome.

These findings underscore the complex genetic architecture of lupus. The identification of specific CNVs associated with the disease provides valuable insights into the underlying mechanisms. These findings may provide a better understanding of the disease process.

A New Era for Lupus Treatment

The research discussed offers an exciting glimpse into the future of lupus treatment. By identifying specific genetic variations associated with the disease, scientists can develop more targeted therapies. For example, understanding the role of the FCGR3B and ADAM3A genes could lead to the development of drugs that specifically address the underlying genetic mechanisms contributing to lupus. Additionally, identifying individuals at higher genetic risk for lupus may enable earlier diagnosis and intervention, potentially improving outcomes and quality of life. This research is an important step towards personalized medicine for lupus and provides real hope for patients and their families.

AI Search Multiple angles on this topic

Toward Precision Care

Expert sources converge on the view that lupus heterogeneity complicates both diagnosis and clinical management, particularly because SLE is relatively uncommon in the general population and may present with variable symptoms and laboratory findings. The Lancet describes SLE through autoantibodies to nuclear antigens, immune-complex deposition, and chronic inflammation affecting organs such as the skin, joints, and kidneys. The 2025 ERN ReCONNET–SLICC–SLEuro consensus reflects an effort by three international SLE expert groups to address therapeutic guidance beyond the common major-organ presentations. These developments support a more individualized model of care, although the overall burden of disease remains high. (Reference URL 1: https://www.thelancet.com/journals/lanrhe/article/PIIS0140-6736(24)00398-2/abstract; Reference URL 2: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00063-3/fulltext)

What Comes Next

Future lupus care is likely to focus not only on suppressing inflammation but also on improving quality of life and reducing comorbid complications. A 2025 review of 2024 research reports advances in pathogenesis, biomarkers, novel therapies, and clinical outcomes, including real-world data supporting anifrolumab and belimumab. U.S. treatment trends from 2007 to 2023 provide an additional basis for examining how care is changing over time. Separately, a market report projects that the systemic lupus erythematosus treatment market could reach USD 12.44 billion by 2035 at a 5.11% compound annual growth rate, although that is a projection rather than a clinical finding. (Reference URL 1: https://pmc.ncbi.nlm.nih.gov/articles/PMC8972918/; Reference URL 2: https://www.clinexprheumatol.org/abstract.asp?a=22258)

Beyond the Immune System

Lupus presents broader challenges because it can affect multiple organs and follow an unpredictable course. The disease burden is shaped not only by inflammation but also by complications, treatment effects, and persistent effects on daily life. Addressing these challenges requires attention to long-term outcomes alongside disease control.

Living With Lupus

For people living with lupus, the practical impact can extend beyond visible symptoms or a single organ problem. Fluctuating disease activity, treatment demands, fatigue, complications, and uncertainty can influence everyday functioning and quality of life. A patient-centered approach must therefore consider both clinical measurements and the lived experience of managing a chronic, variable illness.

Putting the genetic risk estimates in context

  • 1.17 versus 1.15 relative copy numberA separate Chinese comparison found no significant difference in relative FCGR3B copy number between lupus nephritis patients and controls (1.17 versus 1.15; p = 0.627).[1]Caveat: The difference was not statistically significant.

What the genetic clues add up to

Low FCGR3B copy number has been linked to lower FCGR3B membrane expression on neutrophils and less immune-complex clearance. This offers a possible biological route connecting the genetic observation to immune processes, rather than proof that the genetic difference causes lupus nephritis.[2]

How the findings compare across populations and methods

The FCGR3B association has been reported in a Hong Kong Chinese cohort and in a meta-analysis of autoimmune diseases, but these are different kinds of evidence and do not make every population-level result interchangeable.[3] [4]

Other reports have not replicated the low-copy-number association with nephritis in some Asian or Afro-American patient groups. In the cited multivariate analysis, anti-C1q antibody levels had an independent relationship with nephritis, while the FCGR3B result was only borderline.[2]

What remains unresolved about lupus CNVs

  • Would the combined FCGR3B–ADAM3A signal persist in independent samples, given that the ADAM3A association was not replicated by qPCR in a larger population?[5]
  • Why do findings connecting low FCGR3B copy number to lupus nephritis differ across populations and analyses, including reports that did not replicate the association?[1] [2]
  • How much do conclusions about multi-allelic FCGR3 copy-number variation depend on the assay used, and how consistently can independent assays validate the measurements?[6]

Questions about genetic signals

Could genetic findings inform targeted sequencing?

Genetic findings can inform panels designed to target regions of interest that harbor pathogenic mutations, a potential application for clinical care.[7]

Sources

  1. FCGR3B copy number variation is not associated with lupus nephritis in a Chinese population. (pubmed.ncbi.nlm.nih.gov)
  2. Susceptibility for Lupus Nephritis by Low Copy Number of the FCGR3B Gene Is Linked to Increased Levels of Pathogenic Autoantibodies (pmc.ncbi.nlm.nih.gov)
  3. Copy number, linkage disequilibrium and disease association in the FCGR locus (pmc.ncbi.nlm.nih.gov)
  4. Association between FCGR3B copy number variations and susceptibility to autoimmune diseases: a meta-analysis. (pubmed.ncbi.nlm.nih.gov)
  5. Copy number variation in the susceptibility to systemic lupus erythematosus (pmc.ncbi.nlm.nih.gov)
  6. A Comparison of Assays for Accurate Copy Number Measurement of the Low-Affinity Fc Gamma Receptor Genes FCGR3A and FCGR3B (pmc.ncbi.nlm.nih.gov)
  7. Genetic interrogation for sequence and copy number variants in systemic lupus erythematosus (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What are copy number variations (CNVs), and why are they important in understanding lupus?

Copy number variations (CNVs) are differences in the number of copies of specific genes within an individual's DNA. Unlike single-gene mutations, CNVs involve larger segments of DNA and can have profound effects on gene expression and function. They are important in understanding lupus because research is revealing how these CNVs may influence a person's susceptibility to lupus and potentially pave the way for more targeted therapies. Identifying these variations helps scientists understand the genetic architecture of lupus and develop treatments that address the underlying genetic mechanisms.

2

How did the recent study investigate the role of copy number variations (CNVs) in lupus?

The recent study published in PLOS ONE employed a case-control design, comparing the genomes of individuals with systemic lupus erythematosus (SLE) to those without the disease. Researchers used advanced genomic tools to detect and analyze copy number variations (CNVs) across the entire genome. This approach allowed them to identify specific CNVs that are more common in lupus patients compared to healthy individuals, providing insights into the genetic factors influencing the disease.

3

What is the significance of the synergistic effect between the FCGR3B and ADAM3A genes in the context of lupus?

The synergistic effect between the FCGR3B and ADAM3A genes is significant because the research found that when deletions (missing copies) were present in both genes, the risk of developing lupus increased significantly. This suggests that these genes may interact in a way that influences the development of the disease. Understanding this interaction could lead to the development of drugs that specifically target these genes, potentially preventing or treating lupus in individuals with these specific genetic variations. This also underscores the complexity of the genetic factors that contribute to lupus, highlighting that it's often the combination of multiple genetic variations rather than a single gene that increases disease risk.

4

Besides FCGR3B and ADAM3A, what other genes showed deletions in the study, and why is this relevant?

The study identified rare heterozygous deletions in the CFHR4, CFHR5, and HLA-DPB2 genes in lupus patients. This is relevant because these genes are involved in immune system regulation. Deletions in these genes can disrupt normal immune function and potentially contribute to the development of lupus. Further research on these genes could uncover additional pathways involved in the pathogenesis of lupus, offering new targets for therapeutic intervention. The discovery of these deletions expands our understanding of the genetic landscape of lupus and suggests that multiple genetic factors contribute to the disease.

5

How could identifying specific copy number variations (CNVs) lead to improved treatment and management of lupus?

Identifying specific copy number variations (CNVs) associated with lupus enables the development of more targeted therapies. For example, understanding the role of the FCGR3B and ADAM3A genes could lead to the creation of drugs that specifically address the underlying genetic mechanisms contributing to lupus. Furthermore, identifying individuals at higher genetic risk for lupus may enable earlier diagnosis and intervention, potentially improving outcomes and quality of life. This personalized medicine approach offers real hope for patients and their families by tailoring treatments based on their unique genetic profiles. The identification of CNVs also helps refine diagnostic criteria, predict disease progression, and monitor treatment response, leading to more effective and individualized patient care.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.